<DOC>
	<DOCNO>NCT01953848</DOCNO>
	<brief_summary>Tamsulosin ( sell name Omnic OCAS ) use treatment void complaint relate enlarged prostate . Solifenacin ( sell name Vesicare ) use treatment patient suffer problem related overactive bladder , need go toilet frequently often sudden urgent need go toilet . Certain patient enlarge prostate complaint may benefit combination tamsulosin solifenacin . EC905 single tablet contain tamsulosin solifenacin . The current study aim investigate tamsulosin solifenacin take intestine , distribute body eventually eliminate body take single EC905 tablet .</brief_summary>
	<brief_title>A Study Evaluate How Tamsulosin ( 1 Dose ) Solifenacin ( 2 Different Doses ) Are Taken From Intestine , Distributed Through Body Eliminated From Body When Administered Combination Single Tablet ( Called EC905 )</brief_title>
	<detailed_description>In study two sequence group 27 subject total . In Period 1 , subject randomize receive one two final combination tablet formulation tamsulosin HCl solifenacin succinate . In Period 1 , 13 subject receive one combination 14 subject receive combination . In Period 2 , alternate treatment provide . Screening take place Days -21 -2 first admission day ( Day -1 ) . EC905 administer Day 1 Day 12 ( treatment period 1 ) , Day 13 Day 24 ( treatment period 2 ) . All treatment administer subject fast state . Blood sample pharmacokinetic ( PK ) analysis tamsulosin HCl solifenacin free base collect , assessment vital sign , safety electrocardiogram ( ECG ) , safety laboratory , adverse event concomitant medication perform . Subjects discharge day 25 End Study Visit take place least 10 day second treatment period , withdrawal .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Body Mass Index 18.5 30.0 kg/m2 , inclusive . Known suspected hypersensitivity tamsulosin HCl , solifenacin succinate , EC905 component formulation use . Any contraindication precaution use mention applicable section Summary Product Characteristics ( SPC ) tamsulosin solifenacin . Use grapefruit ( 3 x 200 ml ) marmalade ( three time ) week prior admission clinic . Any liver function test ( i.e . ALT , AST ) upper limit normal . Any clinically significant history asthma , eczema , clinically significant allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) . Any contraindication precaution use mention applicable section SPC 's tamsulosin solifenacin . Abnormal pulse rate and/or blood pressure measurement prestudy visit follow : pulse rate &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 160 mmHg ; mean diastolic blood pressure &gt; 100 mmHg ( blood pressure measurement take triplicate subject rest supine position least 5 min ; pulse rate measure automatically ) . A QT interval repeat measurement &gt; 430 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) . Use prescribed OTC ( overthecounter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except paracetamol ( 3 g/day ) . Regular use inducer liver metabolism ( e.g . barbiturate , rifampicin ) 3 month prior admission Clinical Unit . Any use drug abuse within 3 month prior admission Clinical Unit . History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit . History drink 21 unit alcohol per week ( 1 unit = 10 g pure alcohol = 250 ml beer ( 5 % ) 35 ml spirit ( 35 % ) 100 ml wine ( 12 % ) ) within 3 month prior admission Clinical Unit . Donation blood blood product within 3 month prior admission Clinical Unit . Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 . Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life Employee Astellas Group CRO involve study .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Combination tablet EC905</keyword>
	<keyword>Steady-state</keyword>
	<keyword>Vesomni</keyword>
	<keyword>VesiFlow</keyword>
	<keyword>Urizia</keyword>
</DOC>